{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:38:38Z","timestamp":1793219918843,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007174","name":"Pfizer Inc Boulder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007174","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clgc.2021.07.002","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T19:18:53Z","timestamp":1625944733000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1753-5928","authenticated-orcid":false,"given":"Brian A.","family":"Costello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nrupen A.","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-4571","authenticated-orcid":false,"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather","family":"Jim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayer N.","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos E.","family":"Kyriakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Kai","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard J.","family":"Appleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Gartrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-2527","authenticated-orcid":false,"given":"Walter M.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell K.","family":"Pachynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4851-5161","authenticated-orcid":false,"given":"Jack","family":"Mardekian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azah","family":"Borham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2021.07.002_bib0001","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40273-018-0640-7","article-title":"Comparing the relative importance of attributes of metastatic renal cell carcinoma treatments to patients and physicians in the United States: a discrete-choice experiment","volume":"36","author":"Gonzalez","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clgc.2021.07.002_bib0002","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.07.002_bib0003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JOP.2015.004929","article-title":"Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice","volume":"11","author":"Mitchell","year":"2015","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clgc.2021.07.002_bib0004","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2217\/fon-2016-0566","article-title":"Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers","volume":"13","author":"Hutson","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2021.07.002_bib0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdt492","article-title":"Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials","volume":"25","author":"Heng","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2021.07.002_bib0006","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/07357907.2017.1289215","article-title":"Design and rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: a prospective academic and community-based study of patients with metastatic renal cell cancer","volume":"35","author":"Bhavsar","year":"2017","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clgc.2021.07.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.33494","article-title":"Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)","author":"Harrison","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2021.07.002_bib0008","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2021.07.002_bib0009","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/88.12.812","article-title":"Representation of african-americans, hispanics, and whites in National Cancer Institute cancer treatment trials","volume":"88","author":"Tejeda","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2021.07.002_bib0010","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2021.07.002_bib0011","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer, version 3.2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf. Accessed April 7, 2021."},{"key":"10.1016\/j.clgc.2021.07.002_bib0012","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1442-2042.2009.02302.x","article-title":"2009 update on the classification of renal epithelial tumors in adults","volume":"16","author":"Lopez-Beltran","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2021.07.002_bib0013","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2021.07.002_bib0014","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.07.002_bib0015","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.clgc.2017.03.004","article-title":"Comprehensive analysis of survival outcomes in non-clear cell renal cell carcinoma patients treated in clinical trials","volume":"15","author":"de Velasco","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2021.07.002_bib0020","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/03007995.2014.938730","article-title":"Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices","volume":"30","author":"Jonasch","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clgc.2021.07.002_bib0021","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.07.002_bib0022","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.07.002_bib0023","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.07.002_bib0024","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.07.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2021.07.002_bib0026","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321001300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767321001300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:13Z","timestamp":1761564853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767321001300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1558767321001300"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2021.07.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2021.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}